All In MedTech

FDA Clearance Tracker · P020014-S006

ESSURE SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 22, 2004

Approved

Time to decision

227 days

Received Dec 8, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P020014-S006
Device name
ESSURE SYSTEM
Applicant location
Berlin
Received
Dec 8, 2003
Decided
Jul 22, 2004
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P020014

Device type

Device class
Class III
Regulation
21 CFR 884.5380

Every decision under product code HHS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATION OF A WARNING STATEMENT IN THE ESSURE PHYSICIAN LABELING REGARDING THERMAL ENDOMETRIAL ABLATION IN WOMEN WITH ESSURE MICRO-INSERTS IN PLACE.

Source documents

Other decisions for Bayer Pharma AG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.